Supplementary Table S1 from Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma

<p>Supplementary Table S1. Patient Characteristics.</p>

Guardat en:

Dades bibliogràfiques
Autor principal:	Qingsheng Xu (17078830) (author)
Altres autors:	Kaiyuan Huang (17078833) (author), Xiangqi Meng (17078836) (author), Yuxiang Weng (17078839) (author), Luyuan Zhang (17078842) (author), Linghao Bu (17078845) (author), Xiujue Zheng (17078848) (author), Jinquan Cai (17078851) (author), Renya Zhan (17078854) (author), Qun Chen (17078857) (author)
Publicat:	2025
Matèries:	Cancer Clinical Research and Trials Clinical Trial Results Phase II clinical trials CNS Cancers Gliomas, Glioblastomas Precision Medicine
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars